Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

The psychedelic neuroplasticity and safety conundrum: Reaping the rewards of neuroplasticity with caution

By Brian Buntz | April 4, 2023

Digital brain connections spreading out. Artificial intelligence

[nobeastsofierce/Adobe Stock]

Evidence continues to build that serotonergic psychedelics such as psilocybin, DMT, and LSD promote neuroplasticity. Cortical atrophy is involved in the development of a broad swathe of neuropsychiatric conditions ranging from depression to substance use disorder. But it remains unclear how psychedelics may potentially treat mood disorders and other conditions. Despite their therapeutic potential, these compounds continue to remain unpopular in some quarters and could be contraindicated for many individuals even if they ultimately win regulatory approval.

Drug developers, such as Boston-based Delix Therapeutics and Onsero Therapeutics, aim to develop compounds that trigger neuroplasticity in what they deem to be a safer and more accessible therapeutic option than classic psychedelics.

Meanwhile, players such as Compass Pathways (Nasdaq:CMPS) and Small Pharma (CVE:DMT), are working to develop therapies inspired by classic psychedelics.

Neuroplasticity and antidepressant effects

Emerging research in prestigious publications such as Science and Nature continues to strengthen the case that serotonergic psychedelics promote neuroplasticity. Meanwhile, drug developers — most of them relatively small — continue to find that compounds can promote rapid and sustained relief from depressive symptoms.

A phase 2a clinical trial from Small Pharma, for instance, demonstrated that a single dose of N,N-dimethyltryptamine-based SPL026, demonstrated a strong antidepressant effect after one week. In a press release, the company’s chief medical and scientific officer Dr. Carol Routledge noted that “the antidepressant effect was sustained for six months in two-thirds of patients who were in remission at an earlier time-point in the study.”

Small Pharma

Small Pharma’s Combined remission rates from one week to six months after receiving the open-label dose, showing the progression of patients’ remission rates over time. The compiled data includes all individuals who were administered either a single dose or both doses of SPL026. It also includes four participants who were omitted from the official statistical evaluation. These four individuals were given a blinded dose of SPL026 but did not receive a subsequent open-label dose. [Courtesy of Small Pharma]

Robin Carhart-Harris, director of the psychedelics division at the Weill Institute for Neurosciences at the University of California San Francisco, along with Ralph Metzner, distinguished professor of neurology, psychiatry and behavioral sciences, jointly noted that the phase 2a data suggests SPL026 could induce a rapid and sustained antidepressant effect for many patients.Recent neuroimaging and preclinical studies indicate a restorative influence with DMT and similar serotonergic agonists.

Developing non-hallucinogenic psychoplastogens

The use of classic psychedelics, however, is not without risks and limitations. Speaking at a virtual event hosted by Charles River Laboratories, Delix chief scientific officer Dr. Kurt Rasmussen, noted potential safety risks associated with hallucinogens, including psychological distress, psychosis and potential cardiovascular risks. Additionally, Rasmussen highlighted researchers’ currently limited understanding of the optimal therapeutic window and dose frequency to optimize the desired therapeutic effects while minimizing side effects. “If you can eliminate the hallucinogenic effect, but not the efficacy, that would be ideal for many patients who can’t or won’t take hallucinogens,” he said. “If it’s possible to create a compound that has the same beneficial effects as the original but without the hallucinogenic side effects, it could be a promising option for patients who are unable or unwilling to take hallucinogenic compounds,” Rasmussen continued.

The University of California, Davis professor David E. Olson, together with his colleague Valentina Popescu, coined the term “psychoplastogen.” In 2018, Olson wrote that such compounds could lead to a paradigm shift in treating brain disorders, shifting away from correcting “chemical imbalances” toward “achieving selective modulation of neural circuits.”

The term psychoplastogen is “taken from the Greek roots of psych-, plast- and -gen — mind, molding and producing,” Rasumessen said. But the term has the advantage of avoiding “the hallucinogen debate,” he said. “It encompasses the functional activity of the compounds.”

“The concept of ‘psychoplastogens’ may be a useful way to describe these compounds, as it emphasizes their functional activity and ability to produce changes in neuroplasticity without necessarily causing hallucinations,” Rasmussen said.

These compounds promote rapid and enduring neuroplasticity without causing hallucinations. “These compounds are in vitro having an effect. They’re getting in in vivo. They’re clearly changing the morphology, which has a functional effect,” Rasmussen added.

Skipping the trip

Developers of the new therapeutic class are optimistic that they could be safe, fast-acting and long-lasting. Other researchers are working on similar projects, aiming to preserve the ability of psychedelics and ketamine to induce therapeutic changes in the brain while reducing or eliminating the “trip” they create. One example is the Germany-based HMNC Brain Health, which is developing an oral prolonged-release ketamine formulation known as Ketabon (KET01).

In many respects, the interest in off-label use of ketamine for mood disorders has helped lay the groundwork for research into psychoplastogens. That’s because ketamine demonstrated that it is possible to increase neuroplasticity in individuals while decreasing symptoms of depression and anxiety, Rasmussen said. “Ketamine treatment leads to a brief period of disassociation, followed by immediate relief of symptomology that is better the next day and can last for several days,” he said in the Charles River Laboratories event.

Other researchers also note that classic psychedelics have a similar ability to promote neurogenesis and synaptogenesis in vitro and in vivo.


Filed Under: Drug Discovery, Psychiatric/psychotropic drugs
Tagged With: brain disorders, Compass Pathways, Delix Therapeutics, HMNC Brain Health, mental health, neuroplasticity, neuroplastogen, Onsero Therapeutics, psychedelics, research, Small Pharma, therapy, treatment
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
depression sadness and loneliness concept art illustration of wo
Precision psychiatry: A data-driven approach to personalized depression treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE